Skip to content
RDL
Network
Ecosystem
Switch app
TR
About
FAQ
Sign in
Get started
Faculty Opinions recommendation of Selective targeting of lysyl oxidase-like 2 (LOXL2) suppresses hepatic fibrosis progression and accelerates its reversal. — Ralf Weiskirchen | RDL Network
Back
Cite
Save
Save for later
Share
Home
Publications
Faculty Opinions recommendation of Selective targeting of lysyl oxidase-like 2 (LOXL2) suppresses hepatic fibrosis progression and accelerates its reversal.
RW
Shared by
Ralf Weiskirchen
Faculty Opinions recommendation of Selective targeting of lysyl oxidase-like 2 (LOXL2) suppresses hepatic fibrosis progression and accelerates its reversal.
Dataset
en
Authors
RW
Ralf Weiskirchen
Discussion
(0)
Sign in
to like and join the discussion.
No comments yet. Be the first to comment.
Related publications
Article
2017
Lysyl oxidase-like 2 is expressed in kidney tissue and is associated with the progression of tubulointerstitial fibrosis
Sung‐Eun Choi
,
Nara Jeon
,
Hoon Young Choi
,
Jae Il Shin
,
Hyeon Joo Jeong
,
Beom Jin Lim
Dataset
Faculty Opinions recommendation of Helicobacter pylori accelerates hepatic fibrosis by sensitizing transforming growth factor-β1-induced inflammatory signaling.
Ralf Weiskirchen
Dataset
Faculty Opinions recommendation of TLR4 enhances TGF-beta signaling and hepatic fibrosis.
Ralf Weiskirchen
Dataset
Faculty Opinions recommendation of A schistosome miRNA promotes host hepatic fibrosis by targeting transforming growth factor beta receptor III.
Ralf Weiskirchen
,
M Roderfeld
Dataset
Faculty Opinions recommendation of RNA interference targeting the platelet-derived growth factor receptor beta subunit ameliorates experimental hepatic fibrosis in rats.
Ralf Weiskirchen
Discussion(0)
No comments yet. Be the first to comment.